Pierre Fabre Nasodrill Thermal Water Nasal Spray Singapūra - angļu - HSA (Health Sciences Authority)

pierre fabre nasodrill thermal water nasal spray

dch auriga singapore - ear, nose & throat - pierre fabre nasodrill thermal water nasal spray is an isotonic solution made from thermal luchon water (a french hydrotherapy centre producing water extremely rich in sulphur) intended for cleansing the nasal passages, especially in the event of chronic or recurrent infection such as rhinitis or rhinopharyngitis. nasodrill exerts a mechanical washing action which clears the nose and helps to maintain the physiological activity of the nasal membranes.

VINORELBINE PIERRE FABRE vinorelbine 80mg (as tartrate) capsule blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

vinorelbine pierre fabre vinorelbine 80mg (as tartrate) capsule blister pack

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; propylene glycol; hypromellose; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

VINORELBINE PIERRE FABRE vinorelbine 30mg (as tartrate) capsule blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

vinorelbine pierre fabre vinorelbine 30mg (as tartrate) capsule blister pack

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; propylene glycol; hypromellose; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

VINORELBINE PIERRE FABRE vinorelbine 20mg (as tartrate) capsule blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

vinorelbine pierre fabre vinorelbine 20mg (as tartrate) capsule blister pack

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; propylene glycol; hypromellose; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

VINORELBINE PIERRE FABRE vinorelbine 50mg/5mL (as tartrate) injection vial Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

vinorelbine pierre fabre vinorelbine 50mg/5ml (as tartrate) injection vial

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

VINORELBINE PIERRE FABRE vinorelbine 10mg/mL (as tartrate) injection vial Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

vinorelbine pierre fabre vinorelbine 10mg/ml (as tartrate) injection vial

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. vinorelbine pierre fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Vinorelbine Pierre Fabre Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

vinorelbine pierre fabre

pierre fabre medicament australia pty ltd - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg - soft gelatin capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide yellow macrogol 400 medium-chain triglycerides purified water   titanium dioxide

Vinorelbine Pierre Fabre Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

vinorelbine pierre fabre

pierre fabre medicament australia pty ltd - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg - soft gelatin capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide red macrogol 400 medium-chain triglycerides purified water   titanium dioxide

Vinorelbine Pierre Fabre Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

vinorelbine pierre fabre

pierre fabre medicament australia pty ltd - vinorelbine tartrate 55.4mg equivalent to vinorelbine 40 mg - soft gelatin capsule - 40 mg - active: vinorelbine tartrate 55.4mg equivalent to vinorelbine 40 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide red iron oxide yellow macrogol 400 medium-chain triglycerides purified water   titanium dioxide